Research Analysts’ Recent Ratings Updates for Veracyte (VCYT)

Veracyte (NASDAQ: VCYT) has recently received a number of price target changes and ratings updates:

• 7/15/2026 – Veracyte is now covered by Piper Sandler. They set an “overweight” rating and a $66.00 price target on the stock.
• 7/15/2026 – Veracyte is now covered by Piper Sandler. They set an “overweight” rating and a $66.00 price target on the stock.
• 7/14/2026 – Veracyte had its price target raised by Canaccord Genuity Group Inc. from $42.00 to $60.00. They now have a “hold” rating on the stock.
• 7/13/2026 – Veracyte was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/12/2026 – Veracyte was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/9/2026 – Veracyte had its price target raised by Morgan Stanley from $37.00 to $47.00. They now have an “underweight” rating on the stock.
• 7/7/2026 – Veracyte was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/29/2026 – Veracyte had its price target raised by Guggenheim from $45.00 to $65.00. They now have a “buy” rating on the stock.
• 6/27/2026 – Veracyte was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/24/2026 – Veracyte had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 6/2/2026 – Veracyte is now covered by Wolfe Research. They set an “outperform” rating and a $55.00 price target on the stock.
• 6/1/2026 – Veracyte had its price target raised by Needham & Company LLC from $48.00 to $57.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Veracyte was upgraded by Wolfe Research to “strong-buy”.
• 5/28/2026 – Veracyte had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $48.00 price target on the stock.

Insider Transactions at Veracyte

In other news, insider John Leite sold 13,975 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.07, for a total value of $699,728.25. Following the sale, the insider directly owned 132,305 shares in the company, valued at approximately $6,624,511.35. This represents a 9.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Marc Stapley sold 138,051 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.12, for a total value of $6,919,116.12. Following the sale, the chief executive officer directly owned 440,494 shares of the company’s stock, valued at $22,077,559.28. This represents a 23.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 206,696 shares of company stock valued at $10,079,058. Company insiders own 1.60% of the company’s stock.

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.